Evaxion wins FDA fast-track status
The listed biotech company gets a gust of regulatory tailwind in the US for a personalized cancer therapy candidate.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Evaxion Biotech, a Danish biotech company, has received the US Food and Drug Administration’s (FDA) fast-track designation for EVX-01, a personalized cancer therapy candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
